Table of Contents
Volume 2012, Article ID 245037, 7 pages
Review Article

Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease

Shanghai Cardiovascular Institute and Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Received 10 June 2011; Accepted 17 October 2011

Academic Editor: Christian Doutremepuich

Copyright © 2012 Yuxiang Dai and Junbo Ge. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered.